Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies
about
Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus.Disease induction by virus derived from molecular clones of equine infectious anemia virus.Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies.Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horsesEquine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.The efficacy of T cell-mediated immune responses is reduced by the envelope protein of the chimeric HIV-1/SIV-KB9 virus in vivo.Envelope determinants of equine lentiviral vaccine protection.Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.Decreased infectivity of a neutralization-resistant equine infectious anemia virus variant can be overcome by efficient cell-to-cell spread.Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein.Replication in vitro and in vivo of an equine infectious anemia virus mutant deficient in dUTPase activity.Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus.Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process.In vivo dynamics of equine infectious anemia viruses emerging during febrile episodes: insertions/duplications at the principal neutralizing domainEarly detection of dominant Env-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes.Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected ponyB epitopes and selection pressures in feline immunodeficiency virus envelope glycoproteins.The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro.Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.Influence of long terminal repeat and env on the virulence phenotype of equine infectious anemia virus.Adaptive immunity is the primary force driving selection of equine infectious anemia virus envelope SU variants during acute infection.Development of a fluorescence polarization-based diagnostic assay for equine infectious anemia virus.Variability and immunogenicity of caprine arthritis-encephalitis virus surface glycoproteinConservation of human immunodeficiency virus type 1 gp120 inner-domain sequences in lentivirus and type A and B retrovirus envelope surface glycoproteins.An equine infectious anemia virus variant superinfects cells through novel receptor interactions.Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope.Serological method using recombinant S2 protein to differentiate equine infectious anemia virus (EIAV)-infected and EIAV-vaccinated horses.Structural insight into equine lentivirus receptor 1.Examination of potato virus X proteins synthesized in infected tobacco plants.Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.
P2860
Q33349793-D5ACEF89-A1D3-4EE4-9B81-694E854B4032Q33782039-F1C2348C-D9B6-483B-B0C8-976D1D20FF3AQ33840365-44EACEEC-4BA6-4BEF-B442-86F713A7EDB8Q33990657-1BEF25E9-1ACC-4C7D-9621-D17B040D1A72Q34349343-E27F9BD2-06A9-4CE3-8429-7F3EA8172733Q34535707-A6391A7F-7C85-402A-9F46-7ED9B485205DQ34778836-BAAED7D1-FFB8-46D5-A9C8-E2C85C9ACE1FQ35365474-BB78FF22-D94F-4D69-BDD7-26266A58CA54Q35383268-72535E7C-E8EC-4DC2-A505-FA37D28DEC09Q35833979-DFE759E7-CEA0-4464-8BEF-73B6D18C7804Q35838727-8A0EBB76-1600-4EEF-A811-123EFC36A5C3Q35860883-692C9480-1950-491F-A697-38C0154BC6BCQ35883539-7A0D0DA4-6BA7-47A1-B341-3AEC6C2ED2ECQ35887752-362AC291-C07A-4D98-9CB9-E50494D9C27FQ35929492-21706D12-B981-4EA7-908A-9B9545179726Q36549092-3D6E8CFF-DE3C-4265-B089-A452668D7499Q36640639-30F3D0C8-E9F7-4CEA-BB08-6B8900510058Q36698743-0E5818F3-F21A-4256-9070-B8B280F68D49Q36702147-021A3FA3-09E7-476D-9FE4-68B1B7591122Q36953913-CE8F4812-C482-44A3-BDF6-42D148277735Q37349055-780E2573-CD76-491B-A9DF-9FB704DF972FQ39457353-782B1493-2AE7-48B5-A814-AA2F4B2B2ABDQ39591825-891BF787-F3C3-4EE6-B8DB-A55E7C42A943Q39607240-0BB26A47-5D5F-4013-A6ED-BFA85796AC31Q39955743-B5AB77B4-1F91-491B-804F-F85C4B7160DCQ40046473-4D5791FE-1890-49DC-9864-BF63038DA9B6Q40267080-EA5CBAA7-C38B-492B-AE34-DCB63529698EQ40295714-AD3EAF0F-B265-45FB-86C2-151624C122D8Q40309360-327138A8-8C4B-45D5-8F68-37094348AFDBQ41826961-593F64AB-5792-4DAA-984B-79A195FBEACA
P2860
Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Detailed mapping of the antige ...... g synthetic peptide strategies
@ast
Detailed mapping of the antige ...... g synthetic peptide strategies
@en
type
label
Detailed mapping of the antige ...... g synthetic peptide strategies
@ast
Detailed mapping of the antige ...... g synthetic peptide strategies
@en
prefLabel
Detailed mapping of the antige ...... g synthetic peptide strategies
@ast
Detailed mapping of the antige ...... g synthetic peptide strategies
@en
P2093
P2860
P1433
P1476
Detailed mapping of the antige ...... g synthetic peptide strategies
@en
P2093
K E Rushlow
R C Montelaro
P2860
P304
P407
P577
1992-02-01T00:00:00Z